USPTO Technology Center 1600 · BioSeq Examiner Studio

Biotechnology Sequence Alignment, Claim-Feature Strategy & Deduplicated Prior-Art Workbench

Next-Generation Replacement for Legacy ABSS & GenBase UI

Move from WIPO ST.26 sequence listings and claim thresholds to defensible § 102 / § 103 prior art in seconds.

Ingest certified sequence listings directly from SLIC and PE2E-DAV, generate transparent alignment strategies with full examiner sign-off, and inspect deduplicated patent family hits residue by residue.

12 Internal DBs
Pending, Issued, Geneseq, UniProt & GenEmbl
SW · NW · 6-Frame
Real-Time Pairwise & Codon Translation
Okta IAAM SSO
Ephemeral Session Zeroization
USPTO biotechnology sequence examination studio
AU 1642 · Immunology & Therapeutic AntibodiesApp. 18/942,118
Active Examination DocketSEQLIST.XML · 14 Sequences
Humanized Anti-PD-1 / LAG-3 Bispecific Antibody Variable Heavy Chain with pH-Switchable HCDR3 Histidine Dyad
SLIC-2026-0942118-ST26 (Certified)4 Prior-Art Clusters Ranked
PE2E-DAV & SLIC WIPO ST.26 Examination Queue

Select an Active TC-1600 Application Docket or Inspect Custom Sequence

Active Sequence:1..121 (121 aa)
Molecular Weight: 13.62 kDa
Theoretical pI: 7.52
WIPO ST.26 v1.7 Certified
PE2E-DAV Claim Feature ExtractionFiled 2026-03-18 · Primary Examiner Elena Vance, Ph.D.

Claimed Sequence Scope & Structural Constraints

Independent Claim 1 recites a humanized VH domain having >= 85% sequence identity to SEQ ID NO: 1 while strictly retaining Kabat HCDR1 (GYTFTNYYMY), HCDR2 (GINPSNGGTNFNEKFKN), and engineered pH-selective HCDR3 (RDYRFHDMGFDY).

Claim 1 (Independent)
≥ 85% Identity (SEQ ID NO: 1)Motif: RDYRFHDMGFDY

“An isolated bispecific antigen-binding protein comprising a heavy chain variable (VH) domain having at least 85% amino acid sequence identity to SEQ ID NO: 1, wherein the VH domain comprises an HCDR1 of GYTFTNYYMY, an HCDR2 of GINPSNGGTNFNEKFKN, and an HCDR3 comprising RDYRFHDMGFDY.”

Examination Focus: Verify whether prior-art anti-PD-1 histidine-scanned VH disclosures teach H102 insertion inside RDYRFDMGFDY.
Claim 4 (Dependent)
≥ 92% Identity (SEQ ID NO: 1)Motif: RVTLTTDSSTTTAY

“The antigen-binding protein of claim 1, wherein framework region FR3 comprises at least 92% sequence identity to residues 67–98 of SEQ ID NO: 1 and retains Arg71 and Thr73 vernier zone residues.”

Examination Focus: Check human IGHV1-2*02 acceptor framework back-mutations.

Annotated SEQ ID NO: 1 Feature Map

121 residues
QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFHDMGFDYWGQGTTVTVSS
Explainable Search Strategy RecommendationExaminer Status: ACCEPTED

Algorithm, Scoring Matrix & USPTO Database Routing

Why this strategy is recommended: Claim 1 combines an 85% full-length VH identity floor (102/120 aa) with an invariant 12-residue HCDR3 motif (RDYRFHDMGFDY). Smith-Waterman local alignment with BLOSUM62 (gap 11/1) paired with exact HCDR3 motif verification isolates true § 102/§ 103 Pembrolizumab-derived pH-switch variants while filtering thousands of generic human IGHV1-2 framework hits.
Target USPTO Internal Sequence Databases (5 active)Hosted in USPTO AWS Vault

Examiner Human-in-the-Loop Decision Log

Session-Scoped · Non-Training
Accepted Strategy · App. 18/942,11809:14:22 EST
Smith-Waterman · BLOSUM62 (Gap 11/1) · 5 USPTO AA Databases

Confirmed Claim 1 >=85% VH identity + invariant pH-selective HCDR3 motif RDYRFHDMGFDY.